Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 801–900 of 1,000
Khan, T. B., Choudhary, N., Sharma, S., Kumar, D., Kaushik, U., Gupta, V., Gowri, S., Faiyazuddin, M., & Webster, T. J. (2026) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2026.100188 · Cited by 6
Wang, R., Zhang, Z., Du, J., Chen, J., Teng, Y., Wang, Q., Wu, Z., Yang, T., & Jiang, H. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s603425 · Cited by 6
Cao, J., Pickup, S., Rosen, M. A., & Zhou, R. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01824-7 · Cited by 4
“Since a dense stroma is a unique feature of PDA and microvasculature is a stromal component, other stroma-directed drugs are reported to have similar effects on tumor microvasculature [34, 35].”
BackgroundGeller, A. D., Abston, E. D., Muniappan, A., Costantino, C. L., Tang, H., & Lanuti, M. D. (2025) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2025.02.012 · Cited by 4
Guiraldello, R. T., Martins, M. L., & Mancera, P. F. D. A. (2016) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2016.03.019 · Cited by 7
Khalili‐Tanha, G., Khalili‐Tanha, N., Nazari, S. E., Tehrani, N. C., Khazaei, M., Aliakbarian, M., Hassanian, S. M., Ghayour‐Mobarhan, M., Ferns, G. A., & Avan, A. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210625153011 · Cited by 4
Diringer, M., Coliat, P., Mathieu, C., Laurent, N., Mura, C., Banerjee, M., Zhu, C., Grabowska, A. M., Ritchie, A., Clarke, P. A., et al. (2023) · Small · doi:10.1002/smll.202205961 · Cited by 5
Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery
Chaudhary, B., Kumar, P., Arya, P., Singla, D., Kumar, V., Kumar, D., Roshan, S., Wadhwa, S., Gulati, M., Singh, S. K., et al. (2022) · Current Drug Metabolism · doi:10.2174/1389200224666230110145513 · Cited by 5
Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
Li, X., Luo, X., & Hu, S. (2023) · Bioimpacts · doi:10.34172/bi.2023.24166 · Cited by 8
Gabriel, E. M., Bahr, D. A., Rachamalla, H. K., Madamsetty, V. S., Shreeder, B., Bagaria, S. P., Escobedo, A. L., Reid, J. M., & Mukhopadhyay, D. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00078 · Cited by 4
Wright, J. W., Church, K. J., & Harding, J. W. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190326130008 · Cited by 4
Aggrecan: Approaches to Study Biophysical and Biomechanical Properties
Nia, H. T., Christine Ortiz, B., & Grodzinsky, A. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1398-6_17 · Cited by 4
Fixation alters the physical properties of tumor tissue that regulate nanomedicine transport
Martin, J. D., Mpekris, F., Chauhan, V. P., Martin, M. R., Walsh, M. E., Stuber, M. D., McDonald, D. M., Yuan, F., Stylianopoulos, T., & Jain, R. K. (2024) · Drug Delivery · doi:10.1080/10717544.2024.2430528 · Cited by 3
“…that characterizes passive transport through tissue. reduced hydraulic conductivity of the microvascular wall and interstitial space impairs the transport and accumulation of macro-molecular and nanoscale medicines in tumors (Netti et al., 2000; Chauhan et al., 2013; papageorgis et al., 2017).”
Self-citationJalilivand, S., Yazdanparast, S., Bakhtiyaridovvombaygi, M., Izadirad, M., Mikanik, F., & Gharehbaghian, A. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01908-4 · Cited by 4
“This study showed angiotensin inhibitors, known as losartan, not only decreased CAF density, but also decreased hyaluronan and collagen production from CAFs due to affecting downstream signaling pathways [74].”
Qian, G., Zhang, H., Zahm, C. D., & Provenzano, P. P. (2026) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2026.100651 · Cited by 3
Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities
Cremasco, V., & Chang, J. J. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00259 · Cited by 4
The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection
Abe, S., Nakai, Y., Arita, J., Ichida, A., Kawaguchi, Y., Akamatsu, N., Kaneko, J., Ijichi, H., Koike, K., Fujishiro, M., et al. (2024) · Pancreas · doi:10.1097/mpa.0000000000002291 · Cited by 3
The application of nanomaterials in tumor therapy based on the regulation of mechanical properties
Wang, X., Yu, H., Liu, D., Hu, B., Zhang, R., Hu, L., Hu, G., & Li, C. (2024) · Nanoscale · doi:10.1039/d4nr01812e · Cited by 3
Wang, P., Zhang, X., & Shen, J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2463486 · Cited by 3
Palva, R., Parikh, J. R., Suthar, R. M., Saiyed, M., Patel, M., Prajapati, P., & Shah, U. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125805 · Cited by 3
Wu, D., Ji, Y., Ji, W., Tian, H., Dai, Y., Chen, Y., Shen, G., & Yang, G. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00186 · Cited by 3
Tumor Angiogenesis and Modulators
Xu, K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.95139 · Cited by 3
Sehn, F., Büttner, H., Godau, B., Müller, M., Sarcan, S., Offermann, A., Perner, S., Kramer, M. W., Merseburger, A. S., & Roesch, M. C. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08087-5 · Cited by 3
“Inhibition of AT1R has also been shown to improve vascular perfusion of cancers and thereby possibly increases delivery of chemotherapy [15].”
BackgroundIgata, Y., Kojima, M., Suzuki, T., Ishii, G., Morisue, R., Suzuki, T., Kudo, M., Sugimoto, M., Kobayashi, S., Martin, J. D., et al. (2023) · Cancer Science · doi:10.1111/cas.15853 · Cited by 6
Self-citationDynamic monitoring of the fibrosis disease by a collagen targeting near infrared probe
Zhang, X., Yang, Q., Zhou, S., Li, C., & Jiang, X. (2024) · Biomaterials Science · doi:10.1039/d3bm01926h · Cited by 3
Stories of drug repurposing for pancreatic cancer treatment—Past, present, and future
Ilmer, M., Weniger, M., Nieß, H., Wu, Y. F., Zhang, C., Westphalen, C. B., Krüger, S., Angele, M. K., Werner, J. M., D’Haese, J. G., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00009-9 · Cited by 3
Tumor Vascular Remodeling Affects Molecular Dissemination to Lymph Node and Systemic Leukocytes
O’Melia, M. J., Rohner, N. A., & Thomas, S. N. (2022) · Tissue Engineering Part A · doi:10.1089/ten.tea.2022.0020 · Cited by 3
Optimal therapy design with tumor microenvironment normalization
Wang, C., Degnan-Morgenstern, S., Martin, J. D., & Stuber, M. D. (2022) · AIChE Journal · doi:10.1002/aic.17747 · Cited by 3
“Nature Reviews Clinical Oncology 2010;7(11):653– 664.”
BackgroundMethodInfluentialSelf-citationMechanobiology of Autophagy: The Unexplored Side of Cancer
Hernández‐Cáceres, M. P., Munoz, L., Pradenas, J., Pena, F., Lagos, P., Aceitón, P., Owen, G. I., Morselli, E., Criollo, A., Ravasio, A., et al. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.1.2021.40 · Cited by 3
Effect of renin–angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy
Moriyama, S., Hieda, M., Kisanuki, M., Kawano, S., Yokoyama, T., Fukata, M., Kusaba, H., Maruyama, T., Baba, E., Akashi, K., et al. (2022) · Open Heart · doi:10.1136/openhrt-2022-002135 · Cited by 3
Non-invasive assessment for intratumoural distribution of interstitial fluid flow
Zhao, J., Cao, Y., Liu, W., & Han, D. C. (2023) · Magnetic Resonance Letters · doi:10.1016/j.mrl.2023.03.001 · Cited by 3
“Vikash et al. have found that losartan reduces solid stress in tumours, resulting in increased vascular perfusion [22].”
Influence of Renin-angiotensin System Inhibitors on the Treatment of Metastatic Renal Cancer
Saeedi, N., Mansoori, S., Asgharzadeh, F., Soleimani, A., Mollazadeh, S., & Hassanian, S. M. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230524152108 · Cited by 3
Repurposing Tamoxifen for Tumor Microenvironment Priming and Enhanced Tumor‐Targeted Drug Delivery
Biancacci, I., Santis, D. D., Rama, E., Benderski, K., Momoh, J., Pohlberger, R. F., Moeckel, D., Kaps, L., Rijcken, C. J. F., Prakash, J., et al. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300098 · Cited by 4
Tseng, K.-Y., Hsu, C., Shih, Y., Lin, H., Li, Y.-C., Teng, C. J., & Chou, C. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241247019 · Cited by 3
“10,11 However, retrospective studies have reported conflicting results regarding survival outcomes and the use of RAS blockers.”
BackgroundResultRenin-angiotensin-system and clear cell renal carcinoma: research advances and future perspectives
Yang, G., Wang, Y., Lai, Z.-W., Zhang, H., Zhang, Y., & Song, F. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2024.40 · Cited by 6
Wang, N., Liu, J., Wang, W., Qin, J., & Lin, D. (2017) · doi:10.35841/medical-research.1.1.28-34 · Cited by 3
“These results support preclinical evidence that inhibition of Ang II or the Ang II receptor resulted in decompressing blood vessels and improving chemotherapy delivery [39,40].”
ResultThe potential anticancer activities of telmisartan – a literature review
Hadjiyianni, A., & Kalali, D. (2023) · Annales Academiae Medicae Silesiensis · doi:10.18794/aams/163412 · Cited by 3
Tong, Y., He, Y., Hu, L., Liu, Y., Zheng, X., Sun, J., Song, Y., Zhang, Y., Fang, L., & Huang, P. C. (2019) · Tumori Journal · doi:10.1177/0300891619871103 · Cited by 4
Self-citationLange, F., Kirschstein, T., Davis, J. A., Paino, J., Barnes, M. J., Klein, M., Porath, K., Stöhlmacher, P., Fiedler, S., Frank, M., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.001 · Cited by 3
Kraj, L., Chmiel, P., Śliwczyński, A. M., Szymański, Ł., Woźniak, K., Słodkowski, M., Stokłosa, T., & Wyrwicz, L. S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05962-5 · Cited by 3
“Furthermore, there is evidence suggesting that vasodilating drugs can enhance drug delivery and potentiate chemotherapy (Chauhan et al. 2013).”
BackgroundEngineered nanoparticle systems: A review on emerging strategies for enhanced cancer therapeutics
Sivasubramanian, P. D., Unnikrishnan, G., Kolanthai, E., & Senthilkumar, M. (2024) · Next Materials · doi:10.1016/j.nxmate.2024.100405 · Cited by 2
Liu, C., Zhang, H., Gong, J., Xiao, Y., Lin, Y., Peng, W., Pan, X., Li, Y., Jie, H., Qian, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70037 · Cited by 2
Li, Y., Di, X., Chen, J., Wei, J., Li, T., Wang, K., Liao, B., & Luo, D. (2025) · MedComm – Oncology · doi:10.1002/mog2.70048 · Cited by 6
Mirala, F., & Soltani, M. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02051-7 · Cited by 3
Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapy
Hu, X., Wang, Z., Zhu, Y., Ma, P., Zheng, R., Zhi, X., Yan, H., Xiao, T., Tian, J., & Wang, Q. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114745 · Cited by 2
Wang, H., Xu, C. T., Xie, L., Chu, X., Liu, X., & Wang, P. (2026) · Biosensors · doi:10.3390/bios16040189 · Cited by 2
Wang, Y., MaoYan, T., Peng, C., Yang, J., Liu, F., Ding, D., Guo, Y., Yu, Y., & Han, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116821 · Cited by 2
Chen, T.-W., Yu, S., Lu, S.-L., Yeh, C.-H., & Li, P. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01270-x · Cited by 2
“Chemotherapy: Research has explored softening the tumor matrix to enhance drug penetration using stromal modulators such as the angiotensin II receptor blocker losartan [153, 154].”
Tissue mechanopathology of cancer
Ivaska, J., Sale, S., & Yap, A. S. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.06.006 · Cited by 2
Yang, H. Y., Kang, M. Y., Kang, C. M., Lee, W. J., & Hwang, H. K. (2024) · Yonsei Medical Journal · doi:10.3349/ymj.2023.0399 · Cited by 2
“14 .”
BackgroundSkelton, W. P., Masur, J., Thomas, J. V., Fallah, P., Jain, R., Ravi, P. K., Mantia, C. M., McGregor, B. A., Nuzzo, P. V., Adib, E., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102143 · Cited by 3
Self-citationNavigating the nanoscale: Principles of body navigation
Abbasi, S., Dirisala, A., Carter, D. A. G., Paraiso, W. K. D., Li, J., & Tockary, T. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-823994-0.00002-5 · Cited by 2
Boosting pancreatic cancer chemotherapy by disrupting nerve–cancer crosstalk
Xia, Y., & Zhang, J. (2025) · Acta Materia Medica · doi:10.15212/amm-2024-0092 · Cited by 2
“Moreover, substantially greater connective tissue hyperplasia is observed in human pancreatic tumors than in murine orthotopic models [19].”
Kontomaris, S. V., Psychogios, I., Malamou, A., Stylianopoulos, T., & Stylianou, A. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100365 · Cited by 2
Self-citationTassano, M. R., Camacho, X., Freire, T., Perroni, C., da Costa, V., Cabrera, M., García, M. F., Fernández, M., Gambini, J. P., Cabral, P., et al. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0138 · Cited by 2
“17,20,21 Several mAbs targeting the Tn-antigen with different specificities have been developed, some of which have demonstrated increased survival in mice inoculated with Jurkat, 22 mammary, 7 and lung carcinoma cell lines.”
InfluentialLiu, K., Bie, J., Zhang, R., Xiong, R., Peng, L., Luo, Y., Yang, S., Feng, G., & Song, G. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5738 · Cited by 2
“Increasing evidence shows that the inhibitory effect of losartan and candesartan on AGTR1 can inhibit angiogenesis, which helps to inhibit tumor growth and blood metastasis (35,36).”
The Klein–Gordon equation in mixture models of tumour growth
Caviglia, G., Morro, A., & Pinamonti, N. (2014) · Physics Letters A · doi:10.1016/j.physleta.2014.10.018 · Cited by 2
Seton-Rogers, S. E. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3625 · Cited by 2
The AT2 Receptor and Interacting Proteins (ATIPs) in Cancer
Rodrigues, S., Molina, A., Nehlig, A., & Nahmias, C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801364-9.00014-6 · Cited by 2
Delivery of radioimmunotherapy for solid tumors
Gautam, S. K., Dalal, V., Jain, M., & Batra, S. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00016-6 · Cited by 2
Microfluidic Models of the Tumor Microenvironment
Chang, C.-S., Holter, J. C., & Song, J. W. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166013-00252 · Cited by 2
Santamaría, R., Cruz-Caballero, J., Gkontra, P., Jiménez-Montiel, A., Clemente, C., López, J. A., Villalba‐Orero, M., Vázquez, J., Hutloff, A., Lara‐Pezzi, E., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1256127 · Cited by 2
Huang, H., Kovacs, M. E., Aguilera, K. Y., & Brekken, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00007-9 · Cited by 2
Biological barriers to cancer drug delivery, efficacy and cancer models
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00018-4 · Cited by 2
Mehta, A., Hwang, W. L., & Weekes, C. D. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc-2020-pda-05 · Cited by 2
“In particular, losartan has been shown to decrease stromal collagen and HA in desmoplastic tumor models by decreasing not just TGFb signaling, but also connective tissue growth factor, HA synthase 1 and 3, and endothelin-1 (121-123).”
BackgroundPolymer-Based Tumor-targeted Nanosystems
Benli‐Hoppe, T., & Wagner, E. (2020) · Springer eBooks · doi:10.1007/978-981-15-5159-8_11 · Cited by 3
Mechanical Stress-Induced Autophagy: A Key Player in Cancer Metastasis
Das, J., & Maiti, T. K. (2020) · Springer eBooks · doi:10.1007/978-981-15-6930-2_8 · Cited by 2
Mpekris, F., Angeli, S. I., Pirentis, A. P., & Stylianopoulos, T. (2016) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-319-32703-7_120 · Cited by 1
Self-citationPark, K.-L., Han, W. H., Cho, H., Ryu, J., & Kim, Y. (2020) · Daehan nae'si'gyeong bog'gang'gyeong oe'gwa haghoeji/Journal of minimally invasive surgery · doi:10.7602/jmis.2020.23.1.22 · Cited by 1
“Considering oncological viewpoint, to enhance anastomosis site blood perfusion possibly not only promotes anastomotic healing but also magnify the effect of adjuvant chemotherapy [8, 9].”
BackgroundPancreatic adenocarcinoma — current trends in diagnosis and treatment
Gruszczyńska, A., Kowalik, K., Hetman, K., & Modrzejewski, A. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0016 · Cited by 1
Ghafar, M. T. A., & Helmy, A. A. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2023.12.002 · Cited by 1
Saddiqa, A., Andac, C. A., Çakmak, O., Babar, I., & Akhtar, F. (2024) · Kuwait Journal of Science · doi:10.1016/j.kjs.2024.100313 · Cited by 1
Tumor Microcirculation: Abnormalities and Normalization
Fukumura, D. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_13 · Cited by 1
Hsieh, H., Wu, T., Lee, W., Chen, C., Kuo, Y., Lee, H.-Z., & Hour, M. (2025) · American Journal of Cancer Research · doi:10.62347/gwhx6845 · Cited by 1
Advanced strategies to improve the accumulation of nanotherapeutics in tumor
Choudhury, S., Tamang, R., Singh, V., Saad, M., Yadav, P., & Talegaonkar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33343-9.00012-0 · Cited by 1
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer
Lin, E. W., Pathak, P., O’Shea, A., Awasthi, B. W., Phillips, I. E., Kocher, J. R., Song, Y., Raabe, M. J., Xu, K. H., Patel, B. K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2052 · Cited by 1
Wang, J., Ma, Z., Wan, B., & Cui, X. (2025) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-025-00291-7 · Cited by 1
“All pharmacokinetic calculations were performed using WinNonlin software (Pharsight, USA) [15].”
Designing theranostic radiopharmaceutical trials for uterine cervix cancer
Fabian, D., Buffington, M. E., Cagle, B. S., Keefe, S., Schultz, M. K., & Kunos, C. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1708720 · Cited by 1
“In a disease spread to lymph node analysis, sensitivity (86% [31 of 36] vs. 97% [35 of 36]), speci fi city (66% [23 of 35] vs. 100% [35 of 35]), and accuracy (80% [54 of 71] vs. 94% [67 of 71]) were all improved after [ 68 Ga]Ga-FAPI PETCT.”
Abbas, S. F., Abdulwahid, A. B., Omran, D. E., Al-Aubody, N. M., & Albadran, M. F. (2026) · Iraqi National Journal of Medicine · doi:10.37319/iqnjm.8.1.8 · Cited by 1
“Accumulating evidence suggests that ARBs play role in the treatment of breast, prostate and pancreatic tumors, 44-46 and enhance overall survival of the patients.”
Redefining Tumor Vascular Permeability through Deep Learning-Guided Microneedle Delivery
Tian, J., Zhu, M., Guan, Z., Liu, J., Li, Y., Liu, Q., Miao, Y., Wu, J., Zhou, C., Wang, X., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c16558 · Cited by 2
Mechanobiology of non-small cell lung cancer: bridging tumor mechanics and therapeutic strategies
Joshi, R. D., Patil, D. T., & Yadav, K. S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11852-5 · Cited by 1
Najera, J., Chen, H., Batista, B., Ketchum, F., Ali, A., Zorlutuna, P., Howard, S. S., & Datta, M. (2026) · iScience · doi:10.1016/j.isci.2026.115931 · Cited by 1
Chen, K., Xu, D., Zhang, Z. G., Liang, F. Y., He, G. D., Xu, J., & Feng, Q. Y. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01296 · Cited by 1
Li, W., Xin, Y.-Y., Jin, M.-Z., & Jin, W.-L. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103317 · Cited by 4
“In models of pancreatic and breast cancer, Losartan treatment reduces tumor stiffness, improves blood perfusion, and enhances the delivery of both chemotherapeutic agents and immune cells [57,58].”
Riccò, B., Grisendi, G., Monaco, A. L., Giuggioli, D., Clini, E. M., & Dominici, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119626 · Cited by 1
Abu-Rafe, S., Shrem, N. S., Agbarya, A., Miari, A., Brenner, R., Dudnik, Y., Jama, A. A., Shalata, S., Rouvinov, K., Yasin, N. A., et al. (2026) · Medical Sciences · doi:10.3390/medsci14040420 · Cited by 1
“…studies have demonstrated that inhibition of the RAS may reduce tumor-associated fibrosis, normalize tumor vasculature, and enhance infiltration of immune effector cells into the tumor microenvironment, thereby potentially improving antitumor immune responses and therapeutic efficacy [6].”
Wang, Y., Wang, Z., Zhou, F., Qiao, Y., Luo, Z., Wang, F., Yue, B., & Xin, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1946857 · Cited by 2
“Hyaluronan depletion reopened vessels, whereas angiotensin inhibition reduced collagen and hyaluronan, improved perfusion, and enhanced chemotherapy (30, 31).”
Hoang, T. A., Lee, E., Hwang, D., Cho, H. J., & Park, S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115345 · Cited by 1
Cai, W., Dai, S., Chen, Y., Cheng, C., & Chen, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189712 · Cited by 1
SERPINE1 (PAI‐1) Regulation in Mechanotransduction‐Associated Cellular Senescence
Nisa, I. C., Chantachotikul, P., Takahata, K., Ansori, A. N. M., & Deguchi, S. (2026) · Journal of Cellular Biochemistry · doi:10.1002/jcb.70123 · Cited by 1
Liao, Y., Shen, J., Liao, Y., Lin, Y., & Zeng, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1953204 · Cited by 1
“…may normalize tumor vasculature, reduce stromal fibrosis, suppress immunosuppressive myeloid cell populations, and enhance intratumoral CD8 + T-cell infiltration, thereby improving drug delivery and antitumor immune responses (Cortez-Retamozo et al., 2013; Gu et al., 2023; Chauhan et al., 2013).”
Xie, C., Zhu, H., Wen, J., Mo, Y., Wang, W., Chan, C. Y., Lin, X., Huang, X., Li, G., Wu, Y., et al. (2026) · Advanced Materials · doi:10.1002/adma.202523468 · Cited by 1
Oncology-related issues of angiotensin-receptor blockers
Telekes, A., & Kiss, I. (2015) · Orvosi Hetilap · doi:10.1556/oh.2015.30118 · Cited by 1
CCK Receptor Inhibition Reduces Pancreatic Tumor Fibrosis and Promotes Nanoparticle Delivery
Abraham, T., Armold, M., McGovern, C. O., Harms, J. F., Darok, M. C., Gigliotti, C. M., Adair, B. M., Gray, J. L., Kelly, D. F., Adair, J. H., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051024 · Cited by 1
“As such, there is strong evidence that normalizing, but not eliminating, stromal barriers may preserve its restrictive roles while increasing drug efficacy [8,9] and nanoparticle infiltration [10–12].”
BackgroundImproving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies
Dardare, J., Martz, N., Witz, A., Betz, M., Michel, C., Gilson, P., Merlin, J., Lambert, A., & Harlé, A. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.09.013 · Cited by 2
Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance
Akkari, L., & Lujambio, A. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56197-4_3 · Cited by 1
Sanyal, S., Alabraba, E., Hussain, I., Olaru, A., Cameron, I. C., & Gomez, D. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00350-6 · Cited by 1
Gaustad, J., & Rofstad, E. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722773 · Cited by 1
“In addition, PDACs show substantial inter- and intratumor heterogeneity in the physiological tumor microenvironment, suggesting that the aggressive phenotype may be a result of highly heterogenous lesions (21, 26).”
BackgroundIs FOLFIRINOX Better In Primary Resected Metastatic Pancreatic Cancer ?
Yıldırım, S., & Erdoğan, A. P. (2021) · Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi · doi:10.34087/cbusbed.840635 · Cited by 1
The Molecular Mechanisms Involved in Suppressing Triple Negative Breast Cancer Using Natural Agents
Sadik, S. B. S., Sivaprakasam, P., Ramasami, N., & Pandurangan, A. K. (2022) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-9258-8.ch003 · Cited by 2
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.